Curatio iecoris cancer, iecoris cancer curatio consilio modum curatio iecoris cancer, iecoris cancer curatio modus, medicina iecoris cancer tractandi.
Primaria iecoris cancer
Causa primaria iecoris cancer est malignorum tumores et tumore mortes plerumque regionibus quas hominum vita salusque gravantur. Standardising ad iecur cancer diagnosis et curatio est ipsum ad iecur cancer aegris a diagnosis et curatione in meliorem et emendare quale vitae patientibus.
There are many treatment options for iecoris cancer, including surgery, radiotherapy, radiofrequency ablation, venous embolization, and drug treatment. Among them, the chemotherapy effect of liver cancer is not good, because most liver cancer cells are not sensitive to chemotherapeutic drugs, even if the benefit of using chemotherapeutic drugs may be smaller than the side effects. Therefore, the proportion of patients with liver cancer treated with chemotherapy is not large.
Cum MMVII, in adventu Domini sorafenib, primum targeted pro medicamento iecoris cancer, quod habet contritos rei nulla medicina est available ad iecur cancer, sed eam quae est per quam X annis. Tantum sorafenib potest adhiberi curatio, ut prius, linea in iecoris cancer unresectable. Post medicamento resistentia, nec sciunt quomodo eligere?
However, through unremitting efforts, scientists broke through obstacles. In 2018, the second targeted drug that could replace sorafenib was successfully launched, that is, lovatinib! Both sorafenib and lovatinib It is a targeted drug used for first-line treatment of liver cancer. Later, a variety of second-line treatment drugs have also come out one after another!
Since 2017, many new high-level evidences in line with the principles of evidence-based medicine have emerged in the diagnosis, staging and treatment of liver cancer at home and abroad, especially research results adapted to China’s national conditions. This article focuses on the drug treatment plan and sequence in the latest edition of the “Specifications for the Diagnosis and Treatment of Primary Liver Cancer (2019 Edition)”, giving a clear guide for liver cancer friends.
Iecoris cancer curatio FDA guidelines
ad iecur cancer amicis.
| Date | FDA approbat medicamento iecoris cancer targeted | indication | domesticis approbationes |
| 2007-11 | Sorafenib (Sorafenib, Nexavar) | Nam iecoris cancer curatio aut ex unresectable hepatocellular carcinoma | Cibus domestice a enumerantur et operuit medical insurance |
| 2018-8 | Lenvatinib (Levatinib, Lenvima) | Et primo, de recta curatio unresectable hepatocellular carcinoma | domesticis album |
| 2017-4 | Regorafenib (Sigvarga) | Curatio iecoris cancer repugnans sorafenib pro linea secundi, | domesticis foro |
| 2017-9 | Nivolumab (navumab, Opdivo) | Curatio iecoris cancer repugnans sorafenib pro linea secundi, | domesticis foro |
Iecoris cancer curatio est recta electione primi,
(I) Sorafenib
Plures studiorum clinicorum docuerunt Sorafenib certas utilitates superstes habere pro patientibus cancri hepatis progressi in diversis regionibus et locis cum morbis hepatis diversis (gradu indiciorum 1).
Suspendisse formula usus est consuetum voce CD bis quotidie. Class A et B non potest esse per Pugh, puer patientibus iecoris munus. Cum Puellula Pugh B, iecoris munus, Dei Pugh, aegris A 'obvious salvos beneficium est.
Dare operam dapibus HBV iecoris officium promovere iecoris morbo fundamentum in procuratione elit. Plerumque adversa profectae proluvies, ponderis amissa manibus pedibusque syndrome temeraria myocardial ischemia et hypertension solet fieri in principio II ad VI septimanas post curationem.
(II) Lemvatinib
IIb tempus aptum Lenvatinib unresectable tellus, IIIa, IIIb iecur iecoris officium Pugh turpis pueri, et non minus prima acie sorafenib elit. Chlamydia actis iecoris cancer superstes est melius beneficia [CLXXXV] (quod in campester I).
Quia probatus est Lenvatinib iecoris cancer patientibus proficiebat usu in partu Pugh A iecoris cancer. Usu: 12mg, ore semel quotidie ≥60kg pondus; 8mg, ore semel quotidie pondus <60kg. Adversa profectae sunt communia hypertension, fluxus minuitur concupiscentia labore manu pedem syndrome proteinuria nausea et hypothyroidism.
(III) Systematia chemotherapy
FOLFOX4 (fluorouracil, calcium folinatum, oxaliplatin) protocollum approbatur. Sinae curationem hepatis locali progressi et metastatici cancer quae ad resectionem chirurgicam vel localem curationem idonea non est (gradu testimonii I).
Tempus enim studiis II multa referunt systemica cum chemotherapy oxaliplatin combined per sorafenib can amplio objective responsum rates, extend et salvos altiore progressum liberum-salvos et providere bonum salutem (quod de gradu III).
Nam cum aegris bonum iecoris munus et corporis status, est compositum Lorem potest considerari et orci randomized dispensata studiis sunt adhuc opus providere quod summus gradu, secundum quod medicinae. In addition, quaedam metalla trioxide habet effectum in curatio palliativa provectus iecoris cancer (quod de gradu III). Applicationem In orci, oportet caveatur, ne iecoris et renibus usque ad et monitor toxicity.
Secundo, de recta curatio iecoris cancer
(I) Regofini
Quia probatus est in usu scaena cum aegris Regorafenib IIb, IIIª et IIIb CNLC iecoris cancer qui ante fuerat in sorafenib tractata (quod planum I). Quod cum cotidie usus est ad 1mg I ad septimana III weeks omisso.
In Sina, et cum initiali, dose potest esse 80mg 120mg aut, semel in die, crescebatque paulatim et per gradus secundum patientes estote scriptor tolerantia. Communes eventus adversos hypertension, quemadmodum pellem manus pedibus, lassitudine, fluxus.
(II) Navumab et Paimumab
US FDA probavit usum elementorum monoclonalis Navulinu (Nivolumab) et Pabrolizumab elementorum monoclonali (Pembrolizumab) in patientibus cancer hepatis, qui post sorafenib curationem sorafenib priorem (gradum testimonii II) progressus vel tolerare non potest.
Nunc, inhibitores immunologici inhibitores independenter a societatibus Sinensibus evolutae, ut Carellidizum elementorum monoclonales, elementorum monoclonales Treplepril et Xindili elementorum monoclonales, investigationem clinicam patiuntur. Compositum immunotherapy and targeted drugs, chemotherapeutic drugs, and topical treatments is also constantly being explored.
Aliae immunomodulatores (ut interferon α, thymosin α1, etc.), immunotherapy cellulosa (ut receptor chimeric antigen T cell justo, CAR-T, et cytokino interfectori cellae therapiae effecerunt, CIK) omnes antitumores quidam effectus habent. Sed sed orci magna.
